77 research outputs found
Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for OnâDemand HIV Preexposure Prophylaxis
In a randomized, crossover pharmacokinetic study in healthy volunteers (N = 14), a single dose of 2 g probenecid (PRO)âboosted 600 mg tenofovir disoproxil fumarate (TDF)/400 mg emtricitabine (FTC) (test (T) +PRO) was compared with the current onâdemand HIV preexposure prophylaxis from the IPERGAY study (a 600 mg TDF/400 mg FTC on day 1 and 300 mg TDF/200 mg FTC on days 2 and 3) (control, C IPERGAY). PRO increased mean singleâdose area under the plasma concentrationâtime curve extrapolated to infinity (AUC0ââ,SD) of tenofovir (TFV) and FTC by 61% and 68%, respectively. The TFVâdiphosphate (TFVâDP) concentrations in peripheral blood mononuclear cells were higher (~30%) at 24 hours in T +PRO but then fell significantly lower (~40%) at 72 hours compared with C IPERGAY. The interaction between FTC and PRO was unexpected and novel. Further study is needed to determine if this PROâboosted TDF/FTC regimen would be clinically effective
The relation between anger coping strategies, anger mood and somatic complaints in children and adolescents
Attempts to explain the experience of somatic complaints among children and adolescents suggest that they may in part result from the influence of particular strategies for coping with anger on the longevity of negative emotions. To explore these relationships British (n = 393) and Dutch (n = 299) children completed a modified version of the Behavioral Anger Response Questionnaire (BARQ), and two additional questionnaires assessing anger mood and somatic complaints. A hierarchical regression analysis showed that for both the UK and Dutch samples two coping styles, Social support-seeking and Rumination, made a significant contribution to somatic complaints, over and above the variance explained by anger mood. A tendency to repeatedly think or talk about an angering event as a way of coping seems to underlie the observed negative health effects. In addition, tentative support is given for a broader range of strategies to cope with anger than just the traditionally studied anger-out and anger-in styles. Š 2007 Springer Science+Business Media, LLC
Trace elements in hemodialysis patients: a systematic review and meta-analysis
<p>Abstract</p> <p>Background</p> <p>Hemodialysis patients are at risk for deficiency of essential trace elements and excess of toxic trace elements, both of which can affect health. We conducted a systematic review to summarize existing literature on trace element status in hemodialysis patients.</p> <p>Methods</p> <p>All studies which reported relevant data for chronic hemodialysis patients and a healthy control population were eligible, regardless of language or publication status. We included studies which measured at least one of the following elements in whole blood, serum, or plasma: antimony, arsenic, boron, cadmium, chromium, cobalt, copper, fluorine, iodine, lead, manganese, mercury, molybdenum, nickel, selenium, tellurium, thallium, vanadium, and zinc. We calculated differences between hemodialysis patients and controls using the differences in mean trace element level, divided by the pooled standard deviation.</p> <p>Results</p> <p>We identified 128 eligible studies. Available data suggested that levels of cadmium, chromium, copper, lead, and vanadium were higher and that levels of selenium, zinc and manganese were lower in hemodialysis patients, compared with controls. Pooled standard mean differences exceeded 0.8 standard deviation units (a large difference) higher than controls for cadmium, chromium, vanadium, and lower than controls for selenium, zinc, and manganese. No studies reported data on antimony, iodine, tellurium, and thallium concentrations.</p> <p>Conclusion</p> <p>Average blood levels of biologically important trace elements were substantially different in hemodialysis patients, compared with healthy controls. Since both deficiency and excess of trace elements are potentially harmful yet amenable to therapy, the hypothesis that trace element status influences the risk of adverse clinical outcomes is worthy of investigation.</p
Voluntary disclosure of corporate strategy: determinants and outcomes. An empirical study into the risks and payoffs of communicating corporate strategy.
Business leaders increasingly face pressure from stakeholders to be transparent. There
appears however little consensus on the risks and payoffs of disclosing vital information
such as corporate strategy. To fill this gap, this study analyzes firm-specific determinants
and organisational outcomes of voluntary disclosure of corporate strategy. Stakeholder
theory and agency theory help to understand whether companies serve their interest to
engage with stakeholders and overcome information asymmetries. I connect these
theories and propose a comprehensive approach to measure voluntary disclosure of
corporate strategy. Hypotheses from the theoretical framework are empirically tested
through panel regression of data on identified determinants and outcomes and of
disclosed strategy through annual reports, corporate social responsibility reports,
corporate websites and corporate press releases by the 70 largest publicly listed
companies in the Netherlands from 2003 through 2008. I found that industry,
profitability, dual-listing status, national ranking status and listing age have significant
effects on voluntary disclosure of corporate strategy. No significant effects are found for
size, leverage and ownership concentration. On outcomes, I found that liquidity of stock
and corporate reputation are significantly influenced by voluntary disclosure of corporate
strategy. No significant effect is found for volatility of stock. My contributions to theory,
methodology and empirics offers a stepping-stone for further research into understanding
how companies can use transparency to manage stakeholder relations
- âŚ